The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform

C T Guan - One of the best experts on this subject based on the ideXlab platform.

  • preparation of hepatic targeting Antivirus Agent nga acv and its targeting property
    Acta pharmaceutica Sinica, 1996
    Co-Authors: J Z Fan, Q J Pang, C T Guan
    Abstract:

    Neoglycoalbumin (NGA), a special ligend of asialoglycoprotein receptor on the hepatocyte, was linked via a butanediacyl bridge to acyclovir to form a conjugate NGA ACV. By using DTA (Differential thermoanalysis ) and HPLC analysis, ACV was shown to be connected with NGA by covalent bonds and stable in blood. The radio biodistribution of 131 I NGA ACV with high drug density in vivo was carried out in mice. The maximum absorption of 131 I NGA ACV in liver was 81.7±10.4% at 5 min. The radio image of 131 I NGA ACV with high or low drug density in rabbit showed no significant difference in liver targeting property. The competitive connection tests indicated that 131 I NGA ACV was concentrated in liver through receptor mediated mechanism. A tentative test of antihepatitis B of NGA ACV and ACV in vitro showed that the effective dose of the former was significantly lower than that of the latter.

J Z Fan - One of the best experts on this subject based on the ideXlab platform.

  • preparation of hepatic targeting Antivirus Agent nga acv and its targeting property
    Acta pharmaceutica Sinica, 1996
    Co-Authors: J Z Fan, Q J Pang, C T Guan
    Abstract:

    Neoglycoalbumin (NGA), a special ligend of asialoglycoprotein receptor on the hepatocyte, was linked via a butanediacyl bridge to acyclovir to form a conjugate NGA ACV. By using DTA (Differential thermoanalysis ) and HPLC analysis, ACV was shown to be connected with NGA by covalent bonds and stable in blood. The radio biodistribution of 131 I NGA ACV with high drug density in vivo was carried out in mice. The maximum absorption of 131 I NGA ACV in liver was 81.7±10.4% at 5 min. The radio image of 131 I NGA ACV with high or low drug density in rabbit showed no significant difference in liver targeting property. The competitive connection tests indicated that 131 I NGA ACV was concentrated in liver through receptor mediated mechanism. A tentative test of antihepatitis B of NGA ACV and ACV in vitro showed that the effective dose of the former was significantly lower than that of the latter.

Huanchun Chen - One of the best experts on this subject based on the ideXlab platform.

  • effective small interfering rnas targeting matrix and nucleocapsid protein gene inhibit influenza a virus replication in cells and mice
    Antiviral Research, 2007
    Co-Authors: Hongbo Zhou, Meilin Jin, Yaping Peng, Jinlin Liu, Hu Liu, Shengbo Cao, Huanchun Chen
    Abstract:

    RNA interference (RNAi) is a powerful tool to silence gene expression. Small interfering RNA (siRNA)-induced RNA degradation has been recently used as an Antivirus Agent to inhibit specific virus replication. Here, we showed that several siRNAs specific for conserved regions of influenza virus matrix (M2) and nucleocapsid protein (NP) genes could effectively inhibit expression of the corresponding viral protein. We also evaluated the antiviral potential of these siRNAs targeting M2 and NP of H5N1 avian influenza virus (AIV), which are essential to viral replication. We investigated the inhibitory effect of M2-specific siRNAs and NP-specific siRNAs on influenza A virus (H5N1, H1N1 and H9N2) replication in Madin-Darby canine kidney (MDCK) cells and BALB/c mice. The results showed that treatment with these siRNAs could specifically inhibit influenza A virus replication in MDCK cells (0.51-1.63 TCID(50) reduction in virus titers), and delivery of pS-M48 and pS-NP1383 significantly reduced lung virus titers in the infected mice (16-50-fold reduction in lung virus titers) and partially protected the mice from lethal influenza virus challenge (a survival rate of 4/8 for H1N1 virus-infected mice and 2/8 for H5N1 virus infected mice). Moreover, the treatment of pS-M48 and pS-NP1383 could suppress replication of different subtypes of influenza A viruses, including a H5N1 highly pathogenic avian isolate strain. The results provided a basis for further development of siRNA for prophylaxis and therapy of influenza virus infection in humans and animals.

Q J Pang - One of the best experts on this subject based on the ideXlab platform.

  • preparation of hepatic targeting Antivirus Agent nga acv and its targeting property
    Acta pharmaceutica Sinica, 1996
    Co-Authors: J Z Fan, Q J Pang, C T Guan
    Abstract:

    Neoglycoalbumin (NGA), a special ligend of asialoglycoprotein receptor on the hepatocyte, was linked via a butanediacyl bridge to acyclovir to form a conjugate NGA ACV. By using DTA (Differential thermoanalysis ) and HPLC analysis, ACV was shown to be connected with NGA by covalent bonds and stable in blood. The radio biodistribution of 131 I NGA ACV with high drug density in vivo was carried out in mice. The maximum absorption of 131 I NGA ACV in liver was 81.7±10.4% at 5 min. The radio image of 131 I NGA ACV with high or low drug density in rabbit showed no significant difference in liver targeting property. The competitive connection tests indicated that 131 I NGA ACV was concentrated in liver through receptor mediated mechanism. A tentative test of antihepatitis B of NGA ACV and ACV in vitro showed that the effective dose of the former was significantly lower than that of the latter.

Hongbo Zhou - One of the best experts on this subject based on the ideXlab platform.

  • effective small interfering rnas targeting matrix and nucleocapsid protein gene inhibit influenza a virus replication in cells and mice
    Antiviral Research, 2007
    Co-Authors: Hongbo Zhou, Meilin Jin, Yaping Peng, Jinlin Liu, Hu Liu, Shengbo Cao, Huanchun Chen
    Abstract:

    RNA interference (RNAi) is a powerful tool to silence gene expression. Small interfering RNA (siRNA)-induced RNA degradation has been recently used as an Antivirus Agent to inhibit specific virus replication. Here, we showed that several siRNAs specific for conserved regions of influenza virus matrix (M2) and nucleocapsid protein (NP) genes could effectively inhibit expression of the corresponding viral protein. We also evaluated the antiviral potential of these siRNAs targeting M2 and NP of H5N1 avian influenza virus (AIV), which are essential to viral replication. We investigated the inhibitory effect of M2-specific siRNAs and NP-specific siRNAs on influenza A virus (H5N1, H1N1 and H9N2) replication in Madin-Darby canine kidney (MDCK) cells and BALB/c mice. The results showed that treatment with these siRNAs could specifically inhibit influenza A virus replication in MDCK cells (0.51-1.63 TCID(50) reduction in virus titers), and delivery of pS-M48 and pS-NP1383 significantly reduced lung virus titers in the infected mice (16-50-fold reduction in lung virus titers) and partially protected the mice from lethal influenza virus challenge (a survival rate of 4/8 for H1N1 virus-infected mice and 2/8 for H5N1 virus infected mice). Moreover, the treatment of pS-M48 and pS-NP1383 could suppress replication of different subtypes of influenza A viruses, including a H5N1 highly pathogenic avian isolate strain. The results provided a basis for further development of siRNA for prophylaxis and therapy of influenza virus infection in humans and animals.